{"id":307577,"date":"2025-07-15T21:37:49","date_gmt":"2025-07-15T21:37:49","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"modified":"2025-07-15T21:37:49","modified_gmt":"2025-07-15T21:37:49","slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/","title":{"rendered":"Biopharmaceutical Firm&#8217;s Shares Soar Following Favorable Patent Ruling"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\"><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":45,"featured_media":307568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4674],"tags":[28,39,40],"class_list":["post-307577","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-investment","tag-platform","tag-signal"],"acf":{"h1":"Liquidia Technologies stock surges on legal win","h1_source":{"label":"H1","type":"text","formatted_value":"Liquidia Technologies stock surges on legal win"},"description":"Liquidia Technologies experiences dramatic stock price increase after court decision clears path for pulmonary hypertension treatment advancement","description_source":{"label":"Description","type":"textarea","formatted_value":"Liquidia Technologies experiences dramatic stock price increase after court decision clears path for pulmonary hypertension treatment advancement"},"intro":"A significant development in the pharmaceutical industry has emerged as a smaller biopharmaceutical company secured an important legal win that substantially improves its market position and product development prospects.","intro_source":{"label":"Intro","type":"text","formatted_value":"A significant development in the pharmaceutical industry has emerged as a smaller biopharmaceutical company secured an important legal win that substantially improves its market position and product development prospects."},"body_html":"&nbsp;\n\nLiquidia Technologies experienced a remarkable stock price surge on Wednesday following a favorable court ruling in a patent dispute that clears the path for the company's pulmonary arterial hypertension (PAH) treatment.\n<h2>Stock Performance and Market Response<\/h2>\nShares of the biopharmaceutical firm climbed an impressive 36% in mid-day trading, reflecting investors' positive reaction to the legal development. The stock reached $15.54 per share, representing one of its most significant single-day gains in recent history.\n\nThis dramatic price movement follows a sustained period of uncertainty for the company, whose shares had experienced substantial volatility as the patent litigation progressed through the courts. Trading volume also surged substantially above normal levels, indicating heightened investor interest following the announcement.\n<h2>Legal Victory Details<\/h2>\nThe stock price jump came after the United States Court of Appeals for the Federal Circuit rejected an appeal from United Therapeutics, effectively upholding a previous decision that favored Liquidia in the ongoing patent dispute between the two pharmaceutical companies.\n\nThis legal victory removes a significant obstacle that had been hindering Liquidia's ability to advance its YUTREPIA inhalation powder, a treprostinil-based treatment designed for PAH patients. The court's decision essentially validates Liquidia's position that its product does not infringe on United Therapeutics' patents.\n\nThe ruling represents a crucial development for Liquidia, as it allows the company to proceed with its commercialization plans without the legal cloud that had previously hampered investor confidence and strategic planning.\n<h2>Treatment Market Significance<\/h2>\nYUTREPIA represents an important potential entrant in the PAH treatment marketplace, which analysts value at approximately $5 billion globally. The treatment is designed to improve outcomes for patients suffering from this rare but serious condition that causes high blood pressure in the arteries of the lungs.\n\nThe inhalation powder formulation offers potential advantages over existing treatments, including ease of administration and potentially improved therapeutic profiles for certain patient populations.\n\nUnited Therapeutics currently markets Tyvaso, another treprostinil-based inhalation treatment, which generated over $1 billion in sales last year, highlighting the commercial potential of Liquidia's competing product.\n<h2>Executive Commentary<\/h2>\nLiquidia's leadership expressed satisfaction with the court's decision, highlighting its significance for the company's future prospects.\n\n\"Today's decision by the Federal Circuit Court of Appeals affirms what we have always known - Liquidia acted properly in developing YUTREPIA, and we have the right to bring this important new product to PAH patients,\" said Dr. Roger Jeffs, Chief Executive Officer of Liquidia.\n\nHe added, \"This ruling removes a significant obstacle and allows us to focus fully on our upcoming launch preparations. We remain committed to providing PAH patients with an innovative treatment option that can meaningfully improve their quality of life.\"\n\n[cta_button text=\"Start Trading\"]\n<h2>Regulatory Status and Commercial Outlook<\/h2>\nLiquidia received tentative approval from the Food and Drug Administration (FDA) for YUTREPIA in November 2021, but full commercial launch has been delayed pending resolution of the patent litigation with United Therapeutics.\n\nWith this legal hurdle now cleared, analysts anticipate the company will proceed with launch preparations, with potential market entry possible in the coming months, subject to final FDA clearance.\n\nFinancial analysts following the company have begun revising their revenue projections upward, with several noting that YUTREPIA could potentially capture a significant share of the PAH treatment market given its formulation and delivery advantages.\n\nThe company has indicated it is well-positioned to execute a commercial launch, having spent the litigation period building manufacturing capacity and establishing marketing infrastructure in anticipation of a favorable legal outcome.\n\nIndustry observers note that this case represents an important example of how patent litigation can significantly impact smaller pharmaceutical companies' market valuations and commercial prospects, with today's substantial stock movement reflecting the material importance of intellectual property protection in the biopharmaceutical sector.","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<p>&nbsp;<\/p>\n<p>Liquidia Technologies experienced a remarkable stock price surge on Wednesday following a favorable court ruling in a patent dispute that clears the path for the company&#8217;s pulmonary arterial hypertension (PAH) treatment.<\/p>\n<h2>Stock Performance and Market Response<\/h2>\n<p>Shares of the biopharmaceutical firm climbed an impressive 36% in mid-day trading, reflecting investors&#8217; positive reaction to the legal development. The stock reached $15.54 per share, representing one of its most significant single-day gains in recent history.<\/p>\n<p>This dramatic price movement follows a sustained period of uncertainty for the company, whose shares had experienced substantial volatility as the patent litigation progressed through the courts. Trading volume also surged substantially above normal levels, indicating heightened investor interest following the announcement.<\/p>\n<h2>Legal Victory Details<\/h2>\n<p>The stock price jump came after the United States Court of Appeals for the Federal Circuit rejected an appeal from United Therapeutics, effectively upholding a previous decision that favored Liquidia in the ongoing patent dispute between the two pharmaceutical companies.<\/p>\n<p>This legal victory removes a significant obstacle that had been hindering Liquidia&#8217;s ability to advance its YUTREPIA inhalation powder, a treprostinil-based treatment designed for PAH patients. The court&#8217;s decision essentially validates Liquidia&#8217;s position that its product does not infringe on United Therapeutics&#8217; patents.<\/p>\n<p>The ruling represents a crucial development for Liquidia, as it allows the company to proceed with its commercialization plans without the legal cloud that had previously hampered investor confidence and strategic planning.<\/p>\n<h2>Treatment Market Significance<\/h2>\n<p>YUTREPIA represents an important potential entrant in the PAH treatment marketplace, which analysts value at approximately $5 billion globally. The treatment is designed to improve outcomes for patients suffering from this rare but serious condition that causes high blood pressure in the arteries of the lungs.<\/p>\n<p>The inhalation powder formulation offers potential advantages over existing treatments, including ease of administration and potentially improved therapeutic profiles for certain patient populations.<\/p>\n<p>United Therapeutics currently markets Tyvaso, another treprostinil-based inhalation treatment, which generated over $1 billion in sales last year, highlighting the commercial potential of Liquidia&#8217;s competing product.<\/p>\n<h2>Executive Commentary<\/h2>\n<p>Liquidia&#8217;s leadership expressed satisfaction with the court&#8217;s decision, highlighting its significance for the company&#8217;s future prospects.<\/p>\n<p>&#8220;Today&#8217;s decision by the Federal Circuit Court of Appeals affirms what we have always known &#8211; Liquidia acted properly in developing YUTREPIA, and we have the right to bring this important new product to PAH patients,&#8221; said Dr. Roger Jeffs, Chief Executive Officer of Liquidia.<\/p>\n<p>He added, &#8220;This ruling removes a significant obstacle and allows us to focus fully on our upcoming launch preparations. We remain committed to providing PAH patients with an innovative treatment option that can meaningfully improve their quality of life.&#8221;<\/p>\n    <div class=\"po-container po-container_width_article\">\n        <a href=\"\/en\/quick-start\/\" class=\"po-line-banner po-article-page__line-banner\">\n            <svg class=\"svg-image po-line-banner__logo\" fill=\"currentColor\" width=\"auto\" height=\"auto\"\n                 aria-hidden=\"true\">\n                <use href=\"#svg-img-logo-white\"><\/use>\n            <\/svg>\n            <span class=\"po-line-banner__btn\">Start Trading<\/span>\n        <\/a>\n    <\/div>\n    \n<h2>Regulatory Status and Commercial Outlook<\/h2>\n<p>Liquidia received tentative approval from the Food and Drug Administration (FDA) for YUTREPIA in November 2021, but full commercial launch has been delayed pending resolution of the patent litigation with United Therapeutics.<\/p>\n<p>With this legal hurdle now cleared, analysts anticipate the company will proceed with launch preparations, with potential market entry possible in the coming months, subject to final FDA clearance.<\/p>\n<p>Financial analysts following the company have begun revising their revenue projections upward, with several noting that YUTREPIA could potentially capture a significant share of the PAH treatment market given its formulation and delivery advantages.<\/p>\n<p>The company has indicated it is well-positioned to execute a commercial launch, having spent the litigation period building manufacturing capacity and establishing marketing infrastructure in anticipation of a favorable legal outcome.<\/p>\n<p>Industry observers note that this case represents an important example of how patent litigation can significantly impact smaller pharmaceutical companies&#8217; market valuations and commercial prospects, with today&#8217;s substantial stock movement reflecting the material importance of intellectual property protection in the biopharmaceutical sector.<\/p>\n"},"faq":null,"faq_source":{"label":"FAQ","type":"repeater","formatted_value":false}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biopharmaceutical Firm&#039;s Shares Soar Following Favorable Patent Ruling<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biopharmaceutical Firm&#039;s Shares Soar Following Favorable Patent Ruling\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T21:37:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Andrew OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Andrew OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\"},\"author\":{\"name\":\"Andrew OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3\"},\"headline\":\"Biopharmaceutical Firm&#8217;s Shares Soar Following Favorable Patent Ruling\",\"datePublished\":\"2025-07-15T21:37:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\"},\"wordCount\":9,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp\",\"keywords\":[\"investment\",\"platform\",\"signal\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\",\"name\":\"Biopharmaceutical Firm's Shares Soar Following Favorable Patent Ruling\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp\",\"datePublished\":\"2025-07-15T21:37:49+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biopharmaceutical Firm&#8217;s Shares Soar Following Favorable Patent Ruling\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3\",\"name\":\"Andrew OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g\",\"caption\":\"Andrew OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/andrew-ok\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biopharmaceutical Firm's Shares Soar Following Favorable Patent Ruling","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/","og_locale":"en_US","og_type":"article","og_title":"Biopharmaceutical Firm's Shares Soar Following Favorable Patent Ruling","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/","og_site_name":"Pocket Option blog","article_published_time":"2025-07-15T21:37:49+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp","type":"image\/webp"}],"author":"Andrew OK","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Andrew OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"author":{"name":"Andrew OK","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3"},"headline":"Biopharmaceutical Firm&#8217;s Shares Soar Following Favorable Patent Ruling","datePublished":"2025-07-15T21:37:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"wordCount":9,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp","keywords":["investment","platform","signal"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/","name":"Biopharmaceutical Firm's Shares Soar Following Favorable Patent Ruling","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp","datePublished":"2025-07-15T21:37:49+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Biopharmaceutical-Firms-Shares-Soar-Following-Favorable-Patent-Ruling.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"Biopharmaceutical Firm&#8217;s Shares Soar Following Favorable Patent Ruling"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/8c927d60ff98b0ebe00861e922a035d3","name":"Andrew OK","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/383d2c0dd4b219f690be51029697edeb43831adb70c4cbf4f9500ec37448a792?s=96&d=mm&r=g","caption":"Andrew OK"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/andrew-ok\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":307580,"slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","post_title":"Les actions de l'entreprise biopharmaceutique s'envolent apr\u00e8s une d\u00e9cision favorable sur un brevet","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"it_IT":{"locale":"it_IT","id":307581,"slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","post_title":"Le azioni della societ\u00e0 biofarmaceutica salgono dopo una sentenza favorevole sul brevetto","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"pl_PL":{"locale":"pl_PL","id":307583,"slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","post_title":"Akcje firmy biofarmaceutycznej rosn\u0105 po korzystnym orzeczeniu patentowym","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"es_ES":{"locale":"es_ES","id":307578,"slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","post_title":"Las acciones de la empresa biofarmac\u00e9utica se disparan tras un fallo favorable de patente","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"th_TH":{"locale":"th_TH","id":307585,"slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","post_title":"\u0e2b\u0e38\u0e49\u0e19\u0e02\u0e2d\u0e07\u0e1a\u0e23\u0e34\u0e29\u0e31\u0e17\u0e0a\u0e35\u0e27\u0e40\u0e20\u0e2a\u0e31\u0e0a\u0e20\u0e31\u0e13\u0e11\u0e4c\u0e1e\u0e38\u0e48\u0e07\u0e2a\u0e39\u0e07\u0e02\u0e36\u0e49\u0e19\u0e2b\u0e25\u0e31\u0e07\u0e08\u0e32\u0e01\u0e04\u0e33\u0e15\u0e31\u0e14\u0e2a\u0e34\u0e19\u0e2a\u0e34\u0e17\u0e18\u0e34\u0e1a\u0e31\u0e15\u0e23\u0e17\u0e35\u0e48\u0e40\u0e1b\u0e47\u0e19\u0e1a\u0e27\u0e01","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"tr_TR":{"locale":"tr_TR","id":307582,"slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","post_title":"Biyofarmas\u00f6tik Firman\u0131n Hisseleri Olumlu Patent Karar\u0131n\u0131n Ard\u0131ndan Y\u00fckseldi","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"vt_VT":{"locale":"vt_VT","id":307584,"slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","post_title":"C\u1ed5 phi\u1ebfu c\u1ee7a C\u00f4ng ty D\u01b0\u1ee3c ph\u1ea9m Sinh h\u1ecdc T\u0103ng V\u1ecdt Sau Ph\u00e1n Quy\u1ebft B\u1eb1ng S\u00e1ng Ch\u1ebf Thu\u1eadn L\u1ee3i","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"},"pt_AA":{"locale":"pt_AA","id":307579,"slug":"biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling","post_title":"As a\u00e7\u00f5es da empresa biofarmac\u00eautica disparam ap\u00f3s decis\u00e3o favor\u00e1vel sobre patente","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/news\/biopharmaceutical-firms-shares-soar-following-favorable-patent-ruling\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/307577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/45"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=307577"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/307577\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/307568"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=307577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=307577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=307577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}